Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin; it typically develops in early childhood and can persist into adulthood. The standard treatment for AD patients is topical immunotherapy, which has proven broadly effective in managing symptoms. In topical-refractory patients, symptoms are commonly managed by systemic immunomodulators, which pose potentially serious side effects when administered over the long term. The launches of Pfizer’s Eucrisa and Sanofi / Regeneron’s Dupixent have expanded treatment options for AD patients across the severity spectrum. This claims data analysis explores the usage patterns of these newer therapies relative to historical mainstays of treatment and provides valuable insight into evolving drug treatment trends in AD.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric AD patients?
- How have Eucrisa and Dupixent been integrated into the treatment algorithm, and what is their source of business?
- What percentage of pediatric AD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric AD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Sanofi, Regeneron, Eli Lilly, Incyte, AbbVie
Key drugs: Dupixent, Eucrisa, Olumiant, Rinvoq, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, key topical corticosteroids and calcineurin inhibitors
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.